(Journal Article): Modulating the Autoimmune Response in Type 1 Diabetes: A Report on the 64th Scientific Sessions of the ADA, June 2004, Orlando, FL, USA
 
Achenbach P, Fuchtenbusch P (Diabetes Research Institute, Kolner Platz 1, 80804 Munich, Germany, martin.fuechtenbusch(at)lrz.uni-muenchen.de )
 
IN: Rev Diabetic Stud 2004; 1(3):137-140
Impact Factor(s) of Rev Diabetic Stud: 0.125 (2006)

Fulltext:    HTML  PDF

ABSTRACT: Type 1 diabetes mellitus results from a loss of insulin-producing beta-cells in the pancreatic islets caused by an immune-mediated chronic destructive process. It is generally believed that immune tolerance to beta-cells is broken by environmental factors in genetically susceptible individuals, leading to beta-cell destruction that is mediated by T lymphocytes. A key assumption in the current pathogenic concept of type 1 diabetes is a defective immunoregulation affecting both central and peripheral mechanisms of tolerance induction against beta-cell antigens. In animal models of type 1 diabetes, disease-protective modulation of the islet autoimmune response can be effected by various strategies including administration of islet antigens. In human type 1 diabetes, therefore, new strategies are currently being developed with the aim of actively suppressing the autoimmune process and inducing a lasting tolerance against islet antigens. In this context, inducing regulatory T-cells in vivo (i.e. CD4+CD25+ T cells or type 1 regulatory T-cells) is currently becoming more widespread. The following report highlights some of the recent studies on immunotherapy of type 1 diabetes, presented at the 64th Scientific Sessions, held in June 2004, in Orlando, Florida.

TYPE OF PUBLICATION: Conference Report

REFERENCES:

1. Alleva D, Maki R, Putnam A, Kipnes M, Dandona P, Marks, J, Simmons D, Jiminez R, Deboer D, Pan H, Conlon P, Gottlieb P. Modulation of the immune response in type 1 diabetics by NBI-6024, an altered peptide ligand of an immunodominant epitope of insulin. Diabetes 2004. 53(suppl. 2): 45-LB.
2. Lorini R, Minicucci L, Napoli F, Padovani P, Bazzigaluppi E, Cherubini V, Bottazzo F, Pozzilli P, Falorni A, Buzzetti R. HLA Screening for type 1 diabetes at birth in the general population in Italy and implementation of a primary prevention trial with vitamin D and cow’s milk hydrolysate (The PREVEFIN trial). Diabetes 2004. 53(suppl.2):1232.
3. Hummel M, Bonifacio E, Schmid S, Walter M, Knopff A, Ziegler AG. Brief communication: early appearance of islet autoantibodies predicts childhood type 1 diabetes in offspring of diabetic parents. Ann Intern Med 2004. 140:882-886.
4. Herold KC, Gitelman S, Masharani U, Greenbaum C, Hagopian W, Gottlieb P, Muir A, Ramos E, Tomlin N, Bluestone J. Treatment with hOKT3g1 (Ala-Ala) improves insulin response and reduces insulin requirements in patients with new onset type 1 diabetes. Diabetes 2004. 53(suppl.2):271.
5. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA. Anti-CD3 monoclonal antibody in new onset type 1 diabetes mellitus. N Engl J Med 2002. 346:1692-1698.
6. Agardh CD, Cilio CM, Lethagen A, Lynch K, Leslie DG, Palmer M, Harris RA, Robertson J, Lernmark A. Clinical evidence for safety, efficacy, and immunomodulation by a novel therapeutic intended for treatment of autoimmune diabetes. Diabetes 2004. 53(suppl.2):272.
7. Masur K, Beinborn M, Zaenker S. Glucagon-like peptide 1 (GLP-1) is not only an important incretin hormone but also a modulator of the cellular immune system. Diabetes 2004. 53(suppl.2):49-LB.
8. Masur K, Ligon B, Chen C, Beinborn M. Novel Auto-/Paracrine stimulation of GLP-1 receptors contributes to pancreatic beta cell function. Diabetes 2004. 53(suppl.2):73-LB.
9. Kevil CG, Huang M, Siahaan TJ. CD811a Cyclic Peptide Antagonists selectively inhibit T-cell adhesion to pancreatic islet microvascular endothelium: implications for autoimmune diabetes. Diabetes 2004. 53(suppl.2):1227.
10. Achenbach P, Warncke K, Reiter J, Naserke HE, Williams AJ, Bingley PJ, Bonifacio E, Ziegler AG. Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes 2004. 53:384-392.
11. Achenbach P, Koczwara K, Knopff A, Naserke H, Ziegler AG, Bonifacio E. Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J Clin Invest 2004. 114:589-597.